AbbVie Reports Positive Results for Rinvoq in Severe Alopecia Areata Trial

AbbVie has announced promising topline results from Study 2 of its Phase III UP-AA programme, evaluating Rinvoq (upadacitinib) in adults and adolescents (ages 12–64) with severe alopecia areata (AA). Conducted across 248 global sites, the trial included 1,399 participants with an average SALT score of 83.8. In Period A, participants were randomly assigned to receive either 15mg, 30mg Rinvoq, or placebo for 24 weeks. Those on active treatment continued their dosage in Period B, while placebo recipients were re-assigned based on SALT outcomes.

At week 24, 44.6% (15mg) and 54.3% (30mg) of treated patients achieved ≥80% scalp hair regrowth, compared to 3.4% in the placebo group. Notably, 36% and 47.1% achieved ≥90% regrowth, versus 1.4% on placebo. Secondary endpoints also showed notable improvements in eyebrow and eyelash growth. Rinvoq’s safety profile was consistent with prior indications. However, regulatory approval for AA is still pending.

31-07-2025